Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence

Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence

Acute myeloid leukemia (AML) is a highly heterogeneous hematopoietic malignancy characterized by excessive proliferation and accumulation of immature myeloid blasts in the bone marrow. AML has a very poor 5-year survival rate of just 16% in the UK; hence, more efficacious, tolerable, and targeted th...

Full description

Bibliographic Details
Main Authors: Salihanur Darici, Hazem Alkhaldi, Gillian Horne, Heather G. Jørgensen, Sandra Marmiroli, Xu Huang
Format: Article
Language:English
Published: MDPI AG 2020-09-01
Series:Journal of Clinical Medicine
Subjects:
AML
LSC
PI3K/Akt
mTOR
targeted therapy
drug resistance
Online Access:https://www.mdpi.com/2077-0383/9/9/2934

Similar Items

Similar Items